Safety of RSV Preventive Monoclonal Antibody
NCT07158814
This study is recruiting at 5 US sites in 5 states, according to its ClinicalTrials.gov record last updated .
Summary
This is a prospective, randomized, open-label clinical trial to evaluate the safety of administration of respiratory syncytial virus (RSV) preventive monoclonal antibody and other routine childhood vaccines given simultaneously at Visit 1, as compared to sequential administration of respiratory syncytial virus (RSV) preventive monoclonal antibody and other vaccines at separate visits (Visits 1 and 2).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Fever
- Adverse Event Following Immunisation
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 4
- Ages
- 6 to 30 weeks
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Duke University
- Last updated on ClinicalTrials.gov
- March 16, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- Kaiser Permanente Northern California · Oakland, CA
Georgia · 1
- Emory University · Atlanta, GA
New York · 1
- Columbia University · New York, NY
North Carolina · 1
- Duke University · Durham, NC
Ohio · 1
- Cincinnati Children's Hospital Medical Center · Cincinnati, OH
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.